Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application

Key Points

• Safety evaluations demonstrate low toxicity and favorable metabolism in gastrointestinal models, suggesting robust probiotic properties.
• Functional assessments reveal enhanced gut microbiome balance and potential health benefits through metabolism modulation.
• Assessment of genomic data shows a comprehensive understanding of Limosilactobacillus fermentum LF61’s bioactive compounds and pathways.
• Implications underscore the need for further clinical trials to confirm benefits in diverse populations beyond laboratory conditions.